JP2024532705A5 - - Google Patents
Info
- Publication number
- JP2024532705A5 JP2024532705A5 JP2024506734A JP2024506734A JP2024532705A5 JP 2024532705 A5 JP2024532705 A5 JP 2024532705A5 JP 2024506734 A JP2024506734 A JP 2024506734A JP 2024506734 A JP2024506734 A JP 2024506734A JP 2024532705 A5 JP2024532705 A5 JP 2024532705A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL285416A IL285416A (en) | 2021-08-05 | 2021-08-05 | Antibodies for cancer treatment |
| IL285416 | 2021-08-05 | ||
| PCT/IL2022/050849 WO2023012802A1 (en) | 2021-08-05 | 2022-08-04 | Antibodies for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024532705A JP2024532705A (ja) | 2024-09-10 |
| JP2024532705A5 true JP2024532705A5 (https=) | 2025-08-04 |
| JPWO2023012802A5 JPWO2023012802A5 (https=) | 2025-08-04 |
Family
ID=83004541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024506734A Pending JP2024532705A (ja) | 2021-08-05 | 2022-08-04 | 癌を治療するための抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240239886A1 (https=) |
| EP (1) | EP4380975A1 (https=) |
| JP (1) | JP2024532705A (https=) |
| CN (1) | CN118076643A (https=) |
| CA (1) | CA3226996A1 (https=) |
| IL (2) | IL285416A (https=) |
| WO (1) | WO2023012802A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024206738A1 (en) | 2023-03-31 | 2024-10-03 | Immunai Inc. | Humanized anti-trem2 antibodies |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| AR133688A1 (es) * | 2023-08-30 | 2025-10-22 | Teijin Pharma Ltd | Agente terapéutico para enfermedades neurodegenerativas |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130156784A1 (en) * | 2008-08-20 | 2013-06-20 | Michael Jeffers | Compositions Using Antibodies Directed To GPNMB And Uses Thereof |
| WO2017058866A1 (en) * | 2015-09-28 | 2017-04-06 | Precision Immune, Inc. | Anti-trem2 antibodies and uses thereof |
-
2021
- 2021-08-05 IL IL285416A patent/IL285416A/en unknown
-
2022
- 2022-08-04 JP JP2024506734A patent/JP2024532705A/ja active Pending
- 2022-08-04 EP EP22757699.8A patent/EP4380975A1/en active Pending
- 2022-08-04 WO PCT/IL2022/050849 patent/WO2023012802A1/en not_active Ceased
- 2022-08-04 IL IL310605A patent/IL310605A/en unknown
- 2022-08-04 CA CA3226996A patent/CA3226996A1/en active Pending
- 2022-08-04 CN CN202280065311.9A patent/CN118076643A/zh active Pending
-
2024
- 2024-02-05 US US18/432,214 patent/US20240239886A1/en active Pending